Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T16:23:59.696Z.
Calculation as of: 2026-10-06T16:23:59.696Z.
Quote observation: 2026-10-06T16:20:29.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4efcc2f75e7b9d1a3dd193370b83b229becf15f1f7fcdbde4bbae966de3ea950
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$716.46M
PS Ratio
0.89
TTM Avg
1.85
3Y Avg
2.06
5Y Avg
2.04
Market Cap
$717.52M
PS Ratio
12161.36
TTM Avg
4690.70
3Y Avg
1617.75
5Y Avg
973.20
Market Cap
$690.91M
PS Ratio
308.17
TTM Avg
191.08
3Y Avg
130.74
5Y Avg
130.74
Market Cap
$740.76M
PS Ratio
N/A
TTM Avg
1076.18
3Y Avg
1003.10
5Y Avg
1003.10
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | $711.01M | N/A | N/A | N/A | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $716.46M | 0.89 | 1.85 | 2.06 | 2.04 |
| Avalo Therapeutics, Inc. (AVTX)vs › | $717.52M | 12161.36 | 4690.70 | 1617.75 | 973.20 |
| Cytek Biosciences, Inc. (CTKB)vs › | $719.97M | 3.48 | 2.95 | 3.49 | 6.67 |
| ArriVent BioPharma, Inc. (AVBP)vs › | $705.14M | N/A | N/A | N/A | N/A |
| Achieve Life Sciences, Inc. (ACHV)vs › | $735.04M | N/A | 2.39 | 2.16 | 5.43 |
| Anteris Technologies Global Corp. (AVR)vs › | $690.91M | 308.17 | 191.08 | 130.74 | 130.74 |
| Faeth Therapeutics, Inc. (FTH)vs › | $737.27M | N/A | N/A | N/A | N/A |
| Candel Therapeutics, Inc. (CADL)vs › | $740.76M | N/A | 1076.18 | 1003.10 | 1003.10 |
| Helus Pharma Inc. (HELP)vs › | $680.69M | N/A | N/A | N/A | N/A |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-10 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-16 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-12 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-10 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
